CNN - January 12, 2023
Liise-anne Pirofski, M.D., says convalescent plasma, a blood product containing antibodies from people who have recovered from COVID-19, should be among the treatments available to patients with the virus. Dr. Pirofski is chief of infectious diseases at Einstein and Montefiore, professor of medicine and of microbiology & immunology, and holds the Selma and Dr. Jacques Mitrani Chair in Biomedical Research at Einstein.
Dr. Pirofski's ProfileMore coverage on Dr. Pirofski
Medscape - July 26, 2022
Robert Grossberg, M.D., comments on an analysis that found certain anti-viral treatments for COVID-19 may help patients avoid hospitalization or death, but notes that the studies were done only in unvaccinated participants and before the Omicron variant emerged. Dr. Grossberg is associate professor of medicine at Einstein and an infectious disease physician at Montefiore.
Dr. Grossberg's Profile
MedPageToday - June 19, 2022
Liise-anne Pirofski, M.D., co-authored a commentary on the benefits of convalescent plasma for treating immunocompromised patients who have COVID-19. Dr. Pirofski is chief of infectious diseases at Einstein and Montefiore, professor of medicine and of microbiology & immunology, and holds the Selma and Dr. Jacques Mitrani Chair in Biomedical Research at Einstein.
Dr. Pirofski's ProfileMore coverage on Dr. Pirofski
WNYC - May 26, 2022
Seth Congdon, M.D., describes the common and often debilitating symptoms of long COVID and stresses the importance of following up with physicians and specialists to address them. Dr. Congdon is assistant professor of medicine at Einstein and medical co-director of the COVID-19 Recovery (CORE) Clinic at Montefiore.
Dr. Congdon's Profile
National Geographic - November 2, 2022
Betsy Herold, M.D., says that long COVID symptoms that children display—including headaches, mood swings, fatigue, and abdominal pain—may be the result of COVID infection and/or a variety of other causes. Dr. Herold is chief of infectious diseases and vice chair for research in the department of pediatrics at Einstein and the Children's Hospital at Montefiore, and the Harold and Muriel Block Chair in Pediatrics at Einstein.
Dr. Herold's ProfileMore coverage on Dr. Herold
Slate - May 25, 2022
Deepika Slawek, M.D., M.S., explains that a harm reduction approach to COVID-19 means using a range of mitigation measures—such as vaccines, boosters, frequent testing, medical-grade masks, and improved ventilation—to lower the risk of contracting the virus. Dr. Slawek is assistant professor of medicine at Einstein and an internist and infectious disease physician at Montefiore.
Dr. Slawek's ProfileMore coverage on Dr. Slawek
NPR - May 10, 2022
Priya Nori, M.D., says people who are diagnosed with COVID-19 benefit from taking the antiviral medication Paxlovid, even if they have been vaccinated or previously infected. Dr. Nori is associate professor of medicine and of orthopaedic surgery at Einstein and medical director of the antimicrobial stewardship program at Montefiore.
Dr. Nori's ProfileMore coverage on Dr. Nori
UPI - March 11, 2022
Priya Nori, M.D., says the COVID-19 pandemic can be declared over only when there are no new variants on the horizon, a high level of population immunity, and no outbreak hotspots. Dr. Nori is associate professor of medicine and of orthopaedic surgery at Einstein and medical director of the antimicrobial stewardship program at Montefiore.
Dr. Nori's ProfileMore coverage on Dr. Nori
Nature - March 10, 2022
Betsy Herold, M.D., comments on a study that found low levels of antibodies to the SARS-CoV-2 virus in children who have been infected, suggesting they have a weaker adaptive immune response than adults. Dr. Herold is chief of infectious diseases and vice chair for research in the department of pediatrics at Einstein and the Children's Hospital at Montefiore, and the Harold and Muriel Block Chair in Pediatrics at Einstein.
Additional coverage includes MedPageToday
Dr. Herold's ProfileMore coverage on Dr. Herold
Scientific American - January 25, 2022
Betsy Herold, M.D., discusses the innate immune response, which her 2020 research showed was responsible for children's robust response to COVID-19, but she notes that mutations in new viral variants may have an impact on innate immunity. Dr. Herold is chief of infectious diseases and vice chair for research in the department of pediatrics at Einstein and the Children's Hospital at Montefiore and the Harold and Muriel Block Chair in Pediatrics at Einstein.
Dr. Herold's ProfileMore coverage on Dr. Herold
The Washington Post - December 21, 2021
Liise-anne Pirofski, M.D., says the Federal Drug Administration should expand the use of convalescent plasma to outpatient use to help fight COVID-19, particularly during the current surge of the omicron variant. Dr. Pirofski is chief of infectious diseases at Einstein and Montefiore, professor of medicine and of microbiology & immunology, and holds the Selma and Dr. Jacques Mitrani Chair in Biomedical Research at Einstein.
Additional coverage includes The Scientist
Dr. Pirofski's ProfileMore coverage on Dr. Pirofski
Science News - December 21, 2021
Kartik Chandran, Ph.D., says the omicron variant of the coronavirus that causes COVID-19 may be both more transmissible and better able to evade the immune response than previous variants, although more data is needed. Dr. Chandran is professor of microbiology & immunology and the Harold and Muriel Block Faculty Scholar in Virology.
Dr. Chandran's ProfileMore coverage on Dr. Chandran